ANALYSIS OF THE CLINICAL EFFECTIVENESS OF 144 CASES OF SOFT-TISSUE AND SUPERFICIAL MALIGNANT-TUMORS TREATED WITH ELECTROCHEMICAL THERAPY

Authors
Citation
Kh. Quan, ANALYSIS OF THE CLINICAL EFFECTIVENESS OF 144 CASES OF SOFT-TISSUE AND SUPERFICIAL MALIGNANT-TUMORS TREATED WITH ELECTROCHEMICAL THERAPY, The European journal of surgery, 1994, pp. 37-40
Citations number
5
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Surgery
ISSN journal
1102-4151
Year of publication
1994
Supplement
574
Pages
37 - 40
Database
ISI
SICI code
1102-4151(1994):<37:AOTCEO>2.0.ZU;2-M
Abstract
Electrochemical therapy (ECT) was used for the treatment of 144 cases of soft tissue and superficial malignant tumours. All tumours were cyt ologically verified and included 39 soft-tissue sarcomas, ten head-nec k cancers, 21 malignant melanomas, seven skin cancers, three cervical cancers, two breast cancers, 27 recurrent cancers and 35 metastatic ca ncers. The TNM stage of primary cancers were: T-1: n = 28, T-2: n = 36 , T-3: n = 12, and T-4: n = 6. Among these, 23 cases were lymph nodes metastases and 12 systemic metastases. There were 43 cases of localise d recurrent cancer and 19 cases of generalised metastatic disease. ECT was used to treat 128 cases once, nine cases twice, four cases three times and three four times. All patients received systemic chemotherap y for one to two cycles, and three of them were also treated by radiot herapy. The short-term effectiveness rate was 86.87% (125/144) with 81 complete response (CR) (tumour disappeared completely), accounting fo r 58.3% of all cases, 41 partial response (PR) (tumour regressed to mo re than half of its original size) accounting for 28.5%. Fourteen (9.7 %) no change (NC); tumour regressed to less than half of its original size) and five (4.5%) progressive disease (PD); tumour did not regress or even increased in size). The short-term effectiveness rate in rela tion to tumour size was 93.5% (120/127) for tumour diameters of <7 cm and 29.4% (5/17) for tumour diameters >7 cm (p < 0.001). The long-term effectiveness, that is the survival rates for 1, 2, 3 and 3 years, wa s 83.3% (120/144), 74.1% (89/ 120), 84.3% (75/89) and 73.3% (55/75), r espectively. The 4-year survival rate according to the TNM stage of pr imary tumours was T-1: 82%, T-2: 44.1%, T-3: 15-38% and T-4: 0% (p < 0 .001). The 3-year survival rate of the localised recurrent cancers was 94.7% and for the generalised metastatic type 0%. For localised type of metastatic cancer, the 3-year survival rate was 37.5%, but for the generalised type, the 1-year survival rate was 0% (p < 0.001). In conc lusion, our data indicate that the effectiveness of ECT was closely re lated to TNM stage and to tumour size.